Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Ferring Pharmaceuticals Clear all
Completed Phase 3 Interventional Results available

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT02773849
View directory record Official record
Conditions
Superficial Bladder Cancer
Interventions
ADSTILADRIN
Biological
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
34
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Pharmacokinetics and Safety of Testosterone

NCT01370369
View directory record Official record
Conditions
Testicular Hypogonadism
Interventions
Testosterone gel (FE 99903)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

NCT00116779
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Sep 30, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional Results available

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

NCT02663908
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
Male only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.

NCT03069937
View directory record Official record
Conditions
Metastatic Prostatic Adenocarcinoma
Interventions
Docetaxel, Degarelix
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

NCT00477490
View directory record Official record
Conditions
Nocturia
Interventions
desmopressin acetate, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
70
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

NCT01669291
View directory record Official record
Conditions
Fertility
Interventions
Bravelle and Menopur, Agonist, Antagonist
Drug
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel

NCT01665599
View directory record Official record
Conditions
Adult Male Hypogonadism
Interventions
Testosterone gel (FE 999303)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Huntsville, Alabama • Newport Beach, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

NCT02310919
View directory record Official record
Conditions
Infertility
Interventions
Low dose hCG plus FSH co-trigger, Standard dose of hCG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

NCT00296465
View directory record Official record
Conditions
InFertility
Interventions
Pulsatile gonadotropin-releasing hormone (GnRH), Clomiphene Citrate, Placebo Pulsatile GnRH, Placebo Clomiphene Citrate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Sep 30, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

NCT01833065
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Elobixibat 10 mg/day, Elobixibat 5 mg/day, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects and Tolerability With Clenpiq and Low Residue Diet

NCT04150133
View directory record Official record
Conditions
Colonoscopy Preparation
Interventions
Low Residue Diet
Other
Lead sponsor
Hillmont GI
Other
Eligibility
18 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Flourtown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy

NCT03017235
View directory record Official record
Conditions
Bowel Preparation
Interventions
Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution, Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
12
States / cities
Huntsville, Alabama • Anaheim, California • Chula Vista, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 30, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional Results available

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

NCT01827592
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Elobixibat 10 mg, Elobixibat 5 mg, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Foley, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 30, 2026, 1:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

NCT04113382
View directory record Official record
Conditions
Bowel Preparation
Interventions
CLENPIQ, MIRALAX, SENNA
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
12 Months to 8 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Mobile, Alabama • San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 30, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

Fast Track to Fertility

NCT07154888
View directory record Official record
Conditions
Infertility
Interventions
Fast Track to Fertility Algorithmic Text Messaging Platform
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs

NCT01465373
View directory record Official record
Conditions
Infertility
Interventions
Endometrin, Progesterone in Oil
Drug
Lead sponsor
Fertility Centers of Illinois
Other
Eligibility
21 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

NCT01729819
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets, Placebo orally disintegrating tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel

NCT01703741
View directory record Official record
Conditions
Adult Male Hypogonadism
Interventions
Testosterone Gel (FE 999093)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Huntsville, Alabama • Newport Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Early Phase 1 Interventional

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

NCT04301414
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986218 and Degarelix, Degarelix
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

NCT01751451
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)

NCT01283022
View directory record Official record
Conditions
Cervical Ripening, Induction of Labor
Interventions
MVI 200
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Sep 30, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)

NCT04163458
View directory record Official record
Conditions
Infertility
Interventions
MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection)
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Tempe, Arizona • San Diego, California • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 30, 2026, 1:48 PM EDT